Slow-binding inhibition of cholinesterases: Pharmacological, toxicological relevance

Posted by on April 13, 2016 2:42 pm
Categories: health

Researchers describe slow-binding inhibition of cholinesterases and present their pharmacological advantages over classical reversible inhibitors (e.g. long target-residence times, resulting in prolonged efficacy with minimal unwanted side effects), slow-binding inhibitors of ChEs are promising new drugs for treatment of Alzheimer’s disease, myasthenia, and neuroprotection.

Leave a Reply

Your email address will not be published. Required fields are marked *